Shanghai Shen Lian Biomedical Corporation (688098.SH) affiliated company, Shizhiyuan, obtains a patent for the invention of an anti-HIV antibody.

Shanghai Shen Lian Biomedical Corporation (688098.SH) announced that its joint venture company, Yangzhou Shi Zhi Yuan Biotechnology Co., Ltd. (hereinafter referred to as "Shi Zhi Yuan"), recently received an invention patent issued by the National Intellectual Property Office for "Competitive Inhibition of HIV Infection by Monoclonal Antibody Targeting CD4 for the Treatment and Functional Cure of HIV" The patent is related to methods for preventing, treating, and functionally curing HIV infection using CD4 monoclonal antibodies, their combinations, and the use of these combinations. The announcement revealed that Shi Zhi Yuan's pipeline AIDS treatment monoclonal antibody drug UB-421 has a novel mechanism of action. The drug effectively blocks HIV virus from entering host cells through competitive inhibition by binding to the CD4 receptor domain 1 on the surface of targeted T cells. As UB-421 does not directly target the virus genes, the probability of developing drug-resistant mutations is lower compared to existing AIDS treatment drugs in the market. It also has immune modulatory effects. UB-421 will mainly be researched in the areas of multidrug resistance and functional cure in the domestic market.